Drug Trial Radar · NCT06813911
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
246
Actual
Start
Apr 30, 2025
Primary completion
Feb 3, 2028
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
PelacarsenDrug
Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.
PlaceboDrug
Placebo will be provided as solution for injection in prefilled syringe for subcutaneous injection.
InclisiranDrug
All participants will be administered two loading doses of inclisiran as background treatment at Run-in 1 and Run-in 2, separated by 3 months, according to the approved label. After that inclisiran will be administered every 6 months, i.e., Month 5 and Month 11.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in log transformed lipoprotein A (Lp(a)) concentrationTime frame: Baseline, 6 Months
Locations
94 sites in 11 countries. Site status is shown where the registry gives one.
Parkway Medical Center
Birmingham, Alabama
Clinical Research Inst of Arizona
Sun City West, Arizona
National Heart Institute
Beverly Hills, California
Interv Cardiology Med Grp
West Hills, California
Excel Medical Clinical Trials LLC
Boca Raton, Florida
Jacksonville Center for Clinical
Jacksonville, Florida
K2 Medical Research LLC
Maitland, Florida
University of Miami Hospital
Miami, Florida
Baptist Health South
Miami, Florida
Inpatient Research Clinical LLC
Miami Lakes, Florida
FXM Clin Res Miramar LLC
Miramar, Florida
Ocala Cardiovascular Research
Ocala, Florida
SEC Clinical Research
Pensacola, Florida
Peace River Cardiovascular Center
Port Charlotte, Florida
University Of South Florida
Tampa, Florida
FC Site Partners Miami
Winter Park, Florida
Advocate Lutheran General Childrens Hospital
Park Ridge, Illinois
American Health Network Research Dept
Muncie, Indiana
Cardiovascular Associates Research
Covington, Louisiana
Omega Clinical Research
Metairie, Louisiana
Flourish Research Bowie
Bowie, Maryland
Anderson Medical Research
Ft. Washington, Maryland
Henry Ford Hospital
Detroit, Michigan
Aa Mrc Llc
Flint, Michigan
MyMichigan Medical Center Midland
Midland, Michigan
AB Clinical Trials
Las Vegas, Nevada
Overlook Medical Center
Summit, New Jersey
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
The Corvallis Clinic P C
Corvallis, Oregon
Novartis Investigative Site
Tullahoma, Tennessee
PharmaTex Research LLC
Amarillo, Texas
Kelsey Seybold Research Foundation
Houston, Texas
Northwest Houston Clinical Research PLLC
Tomball, Texas
Intermountain Medical Center
Murray, Utah
Virginia Heart
Falls Church, Virginia
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Yinchuan, Ningxia, China
Novartis Investigative Site
Jining, Shandong, China
Novartis Investigative Site
Xian, Shanxi, China
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.